- Joint sales agreement signed for joint cavity injection Conjuran
- Osteoarthritis portfolio complete, together with oral tablet JOINS and dermal patch TRAST
SK chemicals has decided to collaborate with PharmaResearch on its sales of intra-articular injections for osteoarthritis.
SK chemicals (CEO Jeon Kwang-hyun) announced that it has signed a co-promotion agreement with PharmaResearch (CEO Kang Ki-seok, Kim Shin-kyu) on marketing and sales activities targeting general hospitals, which will begin on the 3rd, for the purpose of increasing joint cavity injection Conjuran’s (a medical device) domestic market share.
Through this co-promotion, SK chemicals has secured additional intra-articular injections, strengthening its product lineup for the treatment of osteoarthritis. PharmaResearch is looking forward to gaining access to SK chemicals’ excellent marketing capabilities in the musculoskeletal disorders sector to expand Conjuran’s share of the market.
Conjuran contains the highly viscous sodium polynucleotide, which maintains a constant shape upon being injected into the knee’s articular cavity, reducing joint friction and pain Sodium polynucleotide is an ingredient that has already been used in Europe for over 10 years, the safety and efficacy of which is backed by clinical data.
Conjuran was first released in Korea during the first quarter of 2019. Since March last year, insurance eligibility has expanded to include osteoarthritis, granting patients access to more benefits. Last year, the domestic joint cavity injection market was worth about 100 billion won.
JOINS tablets, SK chemicals’ number one herbal medication that saw 40 billion won in sales, dermal patch TRAST, and the recently added intra-articular injection Conjuran- together form a complete portfolio of treatments for osteoarthritis.
Choi Beom, Marketing Director at PharmaResearch said that “Conjuran has been acclaimed as a new medical technology for patients with knee arthritis. Coverage, which began last year, has laid down a wider foundation. Conjuran is leading a new change in the market for intra-articular injections,” and “based on SK chemicals’ know-how, we will be able to further expand our domestic market share.”
Kim Jeong-hoon, Head of Pharma R&D at SK chemicals, said, “This co-promotion will fortify SK chemicals' position in the musculoskeletal sector,” and “synergies with existing products will contribute to improve the quality of life for domestic consumers.”
[Photo] Osteoarthritis treatment product Conjuran to be jointly sold by SK chemicals and PharmaResearch